A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure

← catalyst calendar

NCT07562087 · readout ≤ 437 d

Sponsored by Tarsus Pharmaceuticals, Inc. (industry) · TARS — their whole pipeline →. With PPD Development, LP.

Phase

Phase 2

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Double · Treatment

Enrollment

722actual

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-03-09

actual

When the study began enrolling

Primary completion

Oct 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Dec 2027

estimated

The whole study's end, after follow-up

First posted

2026-05-01

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-09

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Lyme Disease

Interventions

Drug: TP-05 (lotilaner) Low Dose
Drug: TP-05 (lotilaner) High Dose
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

The Incidence of Treatment Emergent Adverse Events From Baseline

measured From day 1 through the end of study follow-up, an average of 15 months.

Clinically Significant Changes From Baseline Chemistry Laboratory Tests